FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980497811> ?p ?o ?g. }

• W2980497811 endingPage "3155" @default.
• W2980497811 startingPage "3147" @default.
• W2980497811 abstract "Background and Purpose— This study aimed to compare the effectiveness of dual antiplatelet therapy with clopidogrel plus aspirin (DAPT) with that of aspirin monotherapy (AM) in patients with acute, nonminor, and noncardioembolic stroke. Methods— Using a prospective, nationwide, multicenter stroke registry database, acute (within 24 hours of onset), nonminor (baseline National Institutes of Health Stroke Scale score, 4–15), and noncardioembolic stroke patients were identified. Propensity scores using inverse probability of treatment weighting were used to adjust baseline imbalances between the DAPT and AM groups. A primary outcome measure was a composite of all types of stroke (ischemic and hemorrhagic), myocardial infarction, and all-cause mortality within 3 months of stroke onset. Results— Among the 4461 patients meeting the eligibility criteria (age, 69±13 years; men, 57.7%), 52.5% (n=2340) received AM, and 47.5% (n=2121) received DAPT. The primary outcome event was not significantly different between the DAPT group and the AM group (20.9% versus 22.6%, P =0.13). The event rates of all types of stroke were also not different between the 2 groups (19.3% versus 20.1%, P =0.35), while all-cause mortality was significantly lower in the DAPT group than in the AM group (3.4% versus 4.9%, P =0.02). In the propensity-weighted Cox proportional hazards models with robust estimation, DAPT did not reduce the risk of the primary outcome event (hazards ratio, 0.91; 95% CI, 0.79–1.04) but did reduce the risk of all-cause mortality (0.69; 0.49–0.97). There was no treatment heterogeneity among the predefined subgroups, although the potential benefits of DAPT were suggested in subpopulations of moderate-to-severe relevant arterial stenosis and relatively severe deficits (National Institutes of Health Stroke Scale score, 12–15). Conclusions— Compared to AM, clopidogrel plus aspirin did not reduce the risk of the primary outcome event during the first 3 months after a nonminor, noncardioembolic, ischemic stroke." @default.
• W2980497811 created "2019-10-25" @default.
• W2980497811 creator A5000627464 @default.
• W2980497811 creator A5007611070 @default.
• W2980497811 creator A5009410494 @default.
• W2980497811 creator A5009632811 @default.
• W2980497811 creator A5013808765 @default.
• W2980497811 creator A5022150256 @default.
• W2980497811 creator A5022194885 @default.
• W2980497811 creator A5024940863 @default.
• W2980497811 creator A5027700402 @default.
• W2980497811 creator A5029061981 @default.
• W2980497811 creator A5030337320 @default.
• W2980497811 creator A5035023285 @default.
• W2980497811 creator A5035547791 @default.
• W2980497811 creator A5037270738 @default.
• W2980497811 creator A5038364929 @default.
• W2980497811 creator A5039818244 @default.
• W2980497811 creator A5041894132 @default.
• W2980497811 creator A5042618318 @default.
• W2980497811 creator A5045335593 @default.
• W2980497811 creator A5052508004 @default.
• W2980497811 creator A5068131006 @default.
• W2980497811 creator A5070089471 @default.
• W2980497811 creator A5071829277 @default.
• W2980497811 creator A5072472240 @default.
• W2980497811 creator A5077437724 @default.
• W2980497811 creator A5078285341 @default.
• W2980497811 creator A5080790669 @default.
• W2980497811 creator A5083951183 @default.
• W2980497811 creator A5084674542 @default.
• W2980497811 creator A5088274241 @default.
• W2980497811 creator A5088824391 @default.
• W2980497811 creator A5090733758 @default.
• W2980497811 date "2019-11-01" @default.
• W2980497811 modified "2023-09-26" @default.
• W2980497811 title "Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke" @default.
• W2980497811 cites W1969842109 @default.
• W2980497811 cites W2002261049 @default.
• W2980497811 cites W2013606890 @default.
• W2980497811 cites W2077119415 @default.
• W2980497811 cites W2081615170 @default.
• W2980497811 cites W2100092655 @default.
• W2980497811 cites W2124247204 @default.
• W2980497811 cites W2127673268 @default.
• W2980497811 cites W2138595885 @default.
• W2980497811 cites W2149197388 @default.
• W2980497811 cites W2167894791 @default.
• W2980497811 cites W2591456311 @default.
• W2980497811 cites W2739937976 @default.
• W2980497811 cites W2779726076 @default.
• W2980497811 cites W2804570339 @default.
• W2980497811 cites W2903881298 @default.
• W2980497811 doi "https://doi.org/10.1161/strokeaha.119.026044" @default.
• W2980497811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31587655" @default.
• W2980497811 hasPublicationYear "2019" @default.
• W2980497811 type Work @default.
• W2980497811 sameAs 2980497811 @default.
• W2980497811 citedByCount "14" @default.
• W2980497811 countsByYear W29804978112020 @default.
• W2980497811 countsByYear W29804978112021 @default.
• W2980497811 countsByYear W29804978112022 @default.
• W2980497811 countsByYear W29804978112023 @default.
• W2980497811 crossrefType "journal-article" @default.
• W2980497811 hasAuthorship W2980497811A5000627464 @default.
• W2980497811 hasAuthorship W2980497811A5007611070 @default.
• W2980497811 hasAuthorship W2980497811A5009410494 @default.
• W2980497811 hasAuthorship W2980497811A5009632811 @default.
• W2980497811 hasAuthorship W2980497811A5013808765 @default.
• W2980497811 hasAuthorship W2980497811A5022150256 @default.
• W2980497811 hasAuthorship W2980497811A5022194885 @default.
• W2980497811 hasAuthorship W2980497811A5024940863 @default.
• W2980497811 hasAuthorship W2980497811A5027700402 @default.
• W2980497811 hasAuthorship W2980497811A5029061981 @default.
• W2980497811 hasAuthorship W2980497811A5030337320 @default.
• W2980497811 hasAuthorship W2980497811A5035023285 @default.
• W2980497811 hasAuthorship W2980497811A5035547791 @default.
• W2980497811 hasAuthorship W2980497811A5037270738 @default.
• W2980497811 hasAuthorship W2980497811A5038364929 @default.
• W2980497811 hasAuthorship W2980497811A5039818244 @default.
• W2980497811 hasAuthorship W2980497811A5041894132 @default.
• W2980497811 hasAuthorship W2980497811A5042618318 @default.
• W2980497811 hasAuthorship W2980497811A5045335593 @default.
• W2980497811 hasAuthorship W2980497811A5052508004 @default.
• W2980497811 hasAuthorship W2980497811A5068131006 @default.
• W2980497811 hasAuthorship W2980497811A5070089471 @default.
• W2980497811 hasAuthorship W2980497811A5071829277 @default.
• W2980497811 hasAuthorship W2980497811A5072472240 @default.
• W2980497811 hasAuthorship W2980497811A5077437724 @default.
• W2980497811 hasAuthorship W2980497811A5078285341 @default.
• W2980497811 hasAuthorship W2980497811A5080790669 @default.
• W2980497811 hasAuthorship W2980497811A5083951183 @default.
• W2980497811 hasAuthorship W2980497811A5084674542 @default.
• W2980497811 hasAuthorship W2980497811A5088274241 @default.
• W2980497811 hasAuthorship W2980497811A5088824391 @default.
• W2980497811 hasAuthorship W2980497811A5090733758 @default.
• W2980497811 hasBestOaLocation W29804978111 @default.
• W2980497811 hasConcept C126322002 @default.

• next